← All trials
NCT06357182
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2024
- Primary completion
- Mar 8, 2026
- Completion date
- May 29, 2026
- First posted
- Apr 10, 2024
- Last posted
- Jul 19, 2024
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OHSU Knight Cancer InstituteLead sponsor
- OHSU Knight Cancer InstituteSponsor investigator
- OHSU Knight Cancer InstituteOfficial
- Oregon Health and Science UniversityCollaborator
- Oryzon Genomics S.A.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.